U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Lorazepam Injection
Status: Currently in Shortage
»Date first posted: 05/03/2018
»Therapeutic Categories: Neurology

Expand all

Akorn Pharmaceuticals (Revised 03/01/2023)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Lorazepam Injection 2 mg/mL (NDC 17478-040-01) Not available No new manufacturing of product

Amphastar Pharmaceuticals, Inc./IMS (Reverified 01/05/2023)

Company Contact Information:
800-423-4136

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1) Backorder due to the increase in demands Other

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 10/13/2022)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25) This presentation is temporarily on backorder. Additional lots are scheduled for manufacturing and will be available in the October - November 2022 timeframe. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25) This presentation is temporarily on backorder. Additional lots are scheduled for manufacturing and will be available in the October - November 2022 timeframe. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc., a Pfizer company (Revised 03/17/2023)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
2 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1985-30) Available Other
2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02) Discontinued Discontinuation of the manufacture of the drug
Back to Top